Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Zoster Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

NCT01483378
View directory record Official record
Conditions
Herpes Zoster
Interventions
Choosing to receive the vaccine
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

NCT00098046
View directory record Official record
Conditions
Chickenpox, Herpes Zoster
Interventions
famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
1 Year to 12 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

NCT01519570
View directory record Official record
Conditions
Herpes Zoster Disease
Interventions
An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Other
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
2,589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

NCT01165229
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
70 Years and older
Enrollment
14,819 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 6, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MMR and Varicella Vaccine in Premature Infants

NCT00156559
View directory record Official record
Conditions
Chickenpox, Rubella, Rubeola, Mumps
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Months to 16 Months
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 6, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NCT05559671
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

NCT02690207
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
8,687 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
37
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 6, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06581575
View directory record Official record
Conditions
Herpes Zoster (HZ), Infectious Diseases, Shingles
Interventions
JCXH-105, Shingrix
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • Long Beach, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 6, 2026, 4:06 PM EDT
Not listed No phase listed Observational

Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia

NCT01166295
View directory record Official record
Conditions
Neuralgia, Herpes Zoster
Interventions
Not listed
Lead sponsor
Analgesic Solutions
Industry
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Valacyclovir in Immunocompromised Children

NCT00059592
View directory record Official record
Conditions
Shingles, Bone Marrow Transplantation
Interventions
Valacyclovir
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

NCT01331161
View directory record Official record
Conditions
Shingles
Interventions
ZOSTAVAX
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 79 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Tai Chi Chih and Varicella Zoster Immunity

NCT00029484
View directory record Official record
Conditions
Varicella
Interventions
Tai chi chih
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
60 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix®, M-M-R®II, VARIVAX®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
42
States / cities
Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 6, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine

NCT02026089
View directory record Official record
Conditions
Persistence of Varicella Immunity
Interventions
Varicella vaccine
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 6, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

NCT02382588
View directory record Official record
Conditions
Herpes Zoster Keratitis
Interventions
gancyclovir gel, Hypromellose gel
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 95 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

NCT00871117
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Antioch, California • Daly City, California • Hayward, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 6, 2026, 4:06 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age

NCT07742644
View directory record Official record
Conditions
Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
38
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 6, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62 Dose 1, T-62 Dose 2, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Tucson, Arizona • Westlake Village, California • Bradenton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Shingles Prevention Study

NCT00007501
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Varicella-zoster vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
38,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Nudging Patients to Increase Shingles Vaccination

NCT06238726
View directory record Official record
Conditions
Shingles, Vaccination Behavior, Behavior, Health
Interventions
Reminder
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
50 Years and older
Enrollment
50,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 6, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

NCT02979639
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 6, 2026, 4:06 PM EDT